Promising combo takes aim at Hard-to-Treat pancreatic cancer
NCT ID NCT07173387
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a chemotherapy regimen called NALIRIFOX combined with precise radiation (SBRT) in 42 people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach can delay cancer growth and improve survival. Participants receive either early or late radiation after starting chemo, and are followed for at least two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NALIRIFOX chemotherapy (liposomal irinotecan, oxaliplatin, 5-fluorouracil, leucovorin) and Stereotactic Body Radiation Therapy (SBRT)
- What this could lead to
- If successful, this combination could offer a new treatment option to control locally advanced pancreatic cancer and extend survival without surgery.
- What could go wrong
- This is a small Phase 2 trial (42 people) with no control group, so results may not be definitive. Chemotherapy and radiation have significant side effects, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, 0531, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?